Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
Patients with recurrent or refractory Hodgkin’s lymphoma who are at increased risk of progression after high-dose chemotherapy and autologous stem-cell transplantation may benefit from consolidation therapy with brentuximab vedotin, according to the results of the AETHERA study.^1,2^ Based on clinic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-11-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.06.025 |